BR112021002165A2 - composto, composição farmacêutica, e, métodos para tratar uma doença neurodegenerativa e deficiência cognitiva associada ao envelhecimento e neuroinflamação - Google Patents
composto, composição farmacêutica, e, métodos para tratar uma doença neurodegenerativa e deficiência cognitiva associada ao envelhecimento e neuroinflamação Download PDFInfo
- Publication number
- BR112021002165A2 BR112021002165A2 BR112021002165-5A BR112021002165A BR112021002165A2 BR 112021002165 A2 BR112021002165 A2 BR 112021002165A2 BR 112021002165 A BR112021002165 A BR 112021002165A BR 112021002165 A2 BR112021002165 A2 BR 112021002165A2
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- chosen
- alkoxy
- amino
- halo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862714962P | 2018-08-06 | 2018-08-06 | |
| US62/714,962 | 2018-08-06 | ||
| PCT/US2019/045229 WO2020033359A1 (en) | 2018-08-06 | 2019-08-06 | 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021002165A2 true BR112021002165A2 (pt) | 2021-05-04 |
Family
ID=69413327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021002165-5A BR112021002165A2 (pt) | 2018-08-06 | 2019-08-06 | composto, composição farmacêutica, e, métodos para tratar uma doença neurodegenerativa e deficiência cognitiva associada ao envelhecimento e neuroinflamação |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US12195432B2 (https=) |
| EP (1) | EP3833344A4 (https=) |
| JP (2) | JP7422737B2 (https=) |
| KR (1) | KR20210068399A (https=) |
| CN (2) | CN112805000A (https=) |
| AU (1) | AU2019319745B2 (https=) |
| BR (1) | BR112021002165A2 (https=) |
| CA (1) | CA3108773A1 (https=) |
| IL (3) | IL280664B2 (https=) |
| MX (2) | MX2021001456A (https=) |
| SG (1) | SG11202101285YA (https=) |
| TW (1) | TWI904076B (https=) |
| WO (1) | WO2020033359A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12195432B2 (en) | 2018-08-06 | 2025-01-14 | The Board Of Trustees Of The Leland Stanford Junior University | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases |
| KR20220154772A (ko) * | 2020-03-13 | 2022-11-22 | 주식회사 바이오오케스트라 | Pgc-1a 발현을 사용하는 진단 방법 |
| CN112933232A (zh) * | 2021-02-02 | 2021-06-11 | 袁玉佳 | PGC-1α激活TFEB介导的自噬在制备治疗急性肾损伤的药物中的应用 |
| EP4426295A1 (en) * | 2021-11-02 | 2024-09-11 | Tranquis Therapeutics, Inc. | Selection and treatment of subjects having a circulating myeloid cell inflammatory phenotype |
| US20250262189A1 (en) * | 2022-04-22 | 2025-08-21 | Rdiscovery, LLC | Treatment of diseases associated with reductive stress |
| EP4618982A1 (en) * | 2022-11-18 | 2025-09-24 | GOJO, Satoshi | Uses of zln-005 and related compounds |
| WO2024118936A1 (en) * | 2022-12-02 | 2024-06-06 | Tranquis Therapeutics, Inc. | 2-arylbenzimidazole compounds for the treatment of hemoglobinopathies |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE614236A (https=) | 1961-03-01 | |||
| FR1569337A (https=) * | 1968-06-18 | 1969-05-30 | ||
| US4038396A (en) * | 1975-02-24 | 1977-07-26 | Merck & Co., Inc. | Anti-inflammatory oxazole[4,5-b]pyridines |
| GB1584296A (en) | 1976-12-07 | 1981-02-11 | Kanebo Ltd | 2-substituted benzimidazole compounds |
| NZ234564A (en) | 1986-11-21 | 1991-04-26 | Haessle Ab | 1-substituted benzimidazoles and pharmaceutical compositions |
| DE3830060A1 (de) | 1988-09-03 | 1990-03-15 | Boehringer Mannheim Gmbh | 2-phenylbenzimidazole - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
| US5552426A (en) | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
| JPH09169729A (ja) * | 1995-12-19 | 1997-06-30 | Green Cross Corp:The | 非ペプチド型インターロイキン８拮抗剤 |
| CA2258728C (en) * | 1996-06-19 | 2011-09-27 | Rhone Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
| JP2000143635A (ja) * | 1998-06-10 | 2000-05-26 | Takeda Chem Ind Ltd | 血管新生阻害剤 |
| JP2000095767A (ja) * | 1998-09-28 | 2000-04-04 | Takeda Chem Ind Ltd | 性腺刺激ホルモン放出ホルモン拮抗剤 |
| DE59911249D1 (de) | 1998-11-03 | 2005-01-13 | Abbott Gmbh & Co Kg | Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung |
| US20070004713A1 (en) * | 2000-12-07 | 2007-01-04 | Bernard Barlaam | Therapeutic benimidazole compounds |
| DE10134775A1 (de) * | 2001-07-06 | 2003-01-30 | Schering Ag | 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate |
| SE0301371D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | New Compounds |
| KR20070032700A (ko) | 2004-05-20 | 2007-03-22 | 폴드알엑스 파마슈티칼스, 인크. | 트랜스티레틴을 안정화하고 트랜스티레틴 미스폴딩을억제하기 위한, ２-((헤테로)아릴)-벤즈옥사졸 화합물 및유도체, 그리고 조성물 및 방법 |
| RU2007101509A (ru) | 2004-06-17 | 2008-07-27 | Уайт (Us) | Способ получения антагонистов рецепторов гормона, высвобождающего гонадотропин |
| WO2006122546A1 (de) * | 2005-05-18 | 2006-11-23 | Forschungsverbund Berlin E.V. | Nicht-peptidische inhibitoren der akap-pka-wechselwirkung |
| CA2616512A1 (en) | 2005-07-28 | 2007-02-08 | Intervet International B.V. | Novel benzimidazole (thio) carbamates with antiparasitic activity and the synthesis thereof |
| EP1910385B1 (en) | 2005-08-04 | 2013-07-24 | Sirtris Pharmaceuticals, Inc. | Benzothiazoles and thiazolopyridines as sirtuin modulators |
| US7915299B2 (en) | 2006-11-15 | 2011-03-29 | High Point Pharmaceuticals, Llc | 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes |
| GB0807103D0 (en) | 2008-04-18 | 2008-05-21 | Univ Bradford The | Compounds |
| JP2012529449A (ja) * | 2009-06-11 | 2012-11-22 | シエナ ビオテク ソシエタ ペル アチオニ | ヘッジホッグ経路アンタゴニストおよびそれらの治療的応用 |
| WO2011047129A1 (en) * | 2009-10-15 | 2011-04-21 | Southern Research Institute | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such |
| BR112012010738A2 (pt) * | 2009-11-06 | 2019-09-24 | Univ Vanderbilt | ''aril e heteroaril sulfonas como potenciadores alostéricos de mglur4,composições e métodos de tratamento de disfunção neurológica'' |
| GB201009656D0 (en) | 2010-06-09 | 2010-07-21 | Univ St Andrews | Carboxylation catalysts |
| JP5083393B2 (ja) | 2010-09-16 | 2012-11-28 | カシオ計算機株式会社 | 画像表示装置及びプログラム |
| EP2651405A2 (en) * | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| US8865754B2 (en) * | 2011-03-03 | 2014-10-21 | Proteotech Inc. | Compounds for the treatment of neurodegenerative diseases |
| AU2013250726B2 (en) | 2012-04-20 | 2017-01-05 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| EA201590482A1 (ru) * | 2012-09-05 | 2015-07-30 | Байер Кропсайенс Аг | Применение замещенных 2-амидобензимидазолов, 2-амидобензоксазолов и 2-амидобензотиазолов или их солей в качестве биологически активных веществ против абиотического стресса растений |
| KR101435496B1 (ko) | 2012-10-22 | 2014-08-28 | 한국과학기술연구원 | 미토콘드리아 기능 조절제로서의 벤즈이미다졸 유도체 |
| GB201302927D0 (en) * | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| CN103113307B (zh) * | 2013-02-27 | 2015-08-05 | 南京大学 | 苯并咪唑类化合物及其应用 |
| US10022357B2 (en) | 2013-04-29 | 2018-07-17 | The General Hospital Corporation | Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease |
| US10272070B2 (en) | 2014-10-14 | 2019-04-30 | The Board of Trustees of the Leland Stanford Junio r University | Method for treating neurodegenerative diseases |
| CN104873500A (zh) | 2015-04-29 | 2015-09-02 | 中国人民解放军第四军医大学 | 化合物zln005的用途 |
| CA2984971A1 (en) * | 2015-05-11 | 2016-11-17 | Kancera Ab | Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity |
| PT3390367T (pt) * | 2015-12-15 | 2020-09-23 | Univ Leland Stanford Junior | Método para prevenir e/ou tratar enfraquecimento cognitivo e neuroinflamação associados ao envelhecimento |
| RU2747431C2 (ru) * | 2015-12-22 | 2021-05-05 | Кансера Аб | Бициклические гидроксамовые кислоты, полезные в качестве ингибиторов активности деацетилазы гистонов млекопитающих |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| US12195432B2 (en) | 2018-08-06 | 2025-01-14 | The Board Of Trustees Of The Leland Stanford Junior University | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases |
-
2019
- 2019-08-06 US US17/266,433 patent/US12195432B2/en active Active
- 2019-08-06 JP JP2021506624A patent/JP7422737B2/ja active Active
- 2019-08-06 MX MX2021001456A patent/MX2021001456A/es unknown
- 2019-08-06 WO PCT/US2019/045229 patent/WO2020033359A1/en not_active Ceased
- 2019-08-06 IL IL280664A patent/IL280664B2/en unknown
- 2019-08-06 CN CN201980065941.4A patent/CN112805000A/zh active Pending
- 2019-08-06 EP EP19845943.0A patent/EP3833344A4/en active Pending
- 2019-08-06 IL IL307972A patent/IL307972A/en unknown
- 2019-08-06 KR KR1020217006736A patent/KR20210068399A/ko not_active Ceased
- 2019-08-06 CN CN202411199938.0A patent/CN119033775A/zh active Pending
- 2019-08-06 SG SG11202101285YA patent/SG11202101285YA/en unknown
- 2019-08-06 BR BR112021002165-5A patent/BR112021002165A2/pt not_active Application Discontinuation
- 2019-08-06 TW TW108127925A patent/TWI904076B/zh active
- 2019-08-06 CA CA3108773A patent/CA3108773A1/en active Pending
- 2019-08-06 AU AU2019319745A patent/AU2019319745B2/en active Active
- 2019-08-06 IL IL298535A patent/IL298535B2/en unknown
-
2020
- 2020-05-29 US US16/888,040 patent/US10851066B2/en active Active
- 2020-10-13 US US17/068,985 patent/US11111217B2/en active Active
-
2021
- 2021-02-04 MX MX2023012694A patent/MX2023012694A/es unknown
-
2024
- 2024-01-16 JP JP2024004449A patent/JP2024056694A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019319745A1 (en) | 2021-03-25 |
| TW202019410A (zh) | 2020-06-01 |
| US12195432B2 (en) | 2025-01-14 |
| IL280664A (en) | 2021-03-25 |
| US20200299244A1 (en) | 2020-09-24 |
| AU2019319745B2 (en) | 2025-06-26 |
| MX2021001456A (es) | 2021-05-27 |
| IL280664B (en) | 2022-12-01 |
| US20210061769A1 (en) | 2021-03-04 |
| IL307972A (en) | 2023-12-01 |
| IL298535A (en) | 2023-01-01 |
| WO2020033359A1 (en) | 2020-02-13 |
| CN112805000A (zh) | 2021-05-14 |
| SG11202101285YA (en) | 2021-03-30 |
| US11111217B2 (en) | 2021-09-07 |
| TWI904076B (zh) | 2025-11-11 |
| US20210300877A1 (en) | 2021-09-30 |
| CN119033775A (zh) | 2024-11-29 |
| EP3833344A4 (en) | 2022-07-06 |
| IL280664B2 (en) | 2023-04-01 |
| US10851066B2 (en) | 2020-12-01 |
| MX2023012694A (es) | 2023-11-21 |
| JP2021534099A (ja) | 2021-12-09 |
| CA3108773A1 (en) | 2020-02-13 |
| JP7422737B2 (ja) | 2024-01-26 |
| EP3833344A1 (en) | 2021-06-16 |
| IL298535B2 (en) | 2024-03-01 |
| JP2024056694A (ja) | 2024-04-23 |
| KR20210068399A (ko) | 2021-06-09 |
| IL298535B1 (en) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021002165A2 (pt) | composto, composição farmacêutica, e, métodos para tratar uma doença neurodegenerativa e deficiência cognitiva associada ao envelhecimento e neuroinflamação | |
| ES2393425T3 (es) | Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842 | |
| RU2545456C2 (ru) | Pde10 ингибиторы и содержащие их композиции и способы | |
| CA2923269C (en) | Cycloalkyl acid derivative, preparation method thereof, and pharmaceutical application thereof | |
| JP2010529117A (ja) | 代謝型グルタミン酸受容体オキサジアゾールリガンドおよびそれらの増強剤としての使用 | |
| JP2008526999A (ja) | アルツハイマー病治療用ベータ−セクレターゼインヒビターとして活性な置換へテロ環含有三級カルビナミン | |
| JP2010523725A (ja) | 皮膚疾患処置用ホスホジエステラーゼ阻害剤としてのトリアゾロピリジン | |
| AU2012213860A1 (en) | Bicyclic heteroaryl compounds as GPR119 receptor agonists | |
| JPS63502031A (ja) | ヒドロキシおよびアミノチオゾリル−ベンゾジアジノン化合物、これを含む強心性組成物、およびその使用 | |
| EP1797094A2 (en) | 1,3-disubstituted heteroaryl nmda/nr2b antagonists | |
| CN109843879B (zh) | 作为dyrk1抑制剂的苯并噻唑衍生物 | |
| JP7503054B2 (ja) | Ｌｒｒｋ２の野生型および変異型のアザインドール阻害剤 | |
| JP2008527040A (ja) | アルツハイマー病の治療のためのアミノメチルベータセクレターゼ阻害剤 | |
| CN101312978A (zh) | 作为腺苷A2a受体拮抗剂的2－杂芳基－吡唑并－[4,3－e]－1,2,4－三唑并－[1,5－c]－嘧啶 | |
| JP7041141B2 (ja) | 置換された二環式ヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤 | |
| BR112019019740A2 (pt) | compostos heterocíclicos substituídos como moduladores alostéricos de receptores de glutamato metabotrópicos de grupo ii | |
| BR122022025791B1 (pt) | Compostos inibidores duplos de magl e faah, composição farmacêutica e usos | |
| JPWO2000059913A1 (ja) | 新規チアゾロベンゾイミダゾール誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |